David R. Craig is the Chief Executive Officer (CEO) of Sarcomatrix Therapeutics, a biotech company specializing in innovative treatments for muscle diseases. With an MBA from Pepperdine Graziadio Business School, David brings extensive experience in the pharmaceutical and biotech industries. His expertise spans drug development, commercialization, clinical development, and market access. Over the course of his career, David has held executive roles in various biotech and pharmaceutical companies, where he has been instrumental in guiding organizations through critical phases of drug discovery and commercialization. His background also includes strategic advising and consulting, with additional qualifications in project management, lean six sigma, and healthcare information systems. David is currently leading Sarcomatrix Therapeutics through exciting growth phases, driving their mission to develop breakthrough therapies that address unmet needs in muscle diseases. Under his leadership, the company has gained recognition for its innovation and market potential.